Arcturus Therapeutics Holdings IncQ) expected to post a loss of 90 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Arcturus Therapeutics Holdings IncQ) is projected to report a loss of 90 cents per share and a 55% decline in quarterly revenue to $22.435 million for the period ending June 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $48.00, significantly above its last closing price of $12.21. Recent quarterly performances show a mix of beats and misses against estimates, with the latest earnings estimate unchanged over the past three months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments